Yes, so the TANGENT trial was a randomized phase 3 placebo-controlled trial of a CSF1R antibody in tenosynovial giant cell tumor, or TGCT. And the primary endpoint of the trial was response rate in the antibody arm compared to the placebo arm. And the trial met the primary endpoint, but also showed significant benefit for the antibody in terms of pain, function, and other quality of life measures...
Yes, so the TANGENT trial was a randomized phase 3 placebo-controlled trial of a CSF1R antibody in tenosynovial giant cell tumor, or TGCT. And the primary endpoint of the trial was response rate in the antibody arm compared to the placebo arm. And the trial met the primary endpoint, but also showed significant benefit for the antibody in terms of pain, function, and other quality of life measures. The notable thing about this trial compared to previous randomized trials in TGCT of CSF1R inhibitors was that this was a defined course of therapy for five cycles and over 75% of the patients continued to receive up to five cycles of treatment. This was the six-month analysis and of course we really eagerly await further follow-up because this trial will help to define the role of a defined course of therapy in TGCT.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.